Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Johnson & Johnson gets subpoena on recalls

chart_jnj_ytd.top.gif By Parija Kavilanz, senior writer


NEW YORK (CNNMoney.com) -- Drugmaker Johnson & Johnson said Tuesday that it has received a grand jury subpoena and is cooperating with a federal investigation stemming from multiple recalls of its popular non-prescription drugs.

The company, which also reported its quarterly results, said it was addressing a variety of legal actions, including lawsuits against its McNeil Consumer Healthcare unit, ongoing investigations into the recalls and a grand jury subpoena from the U.S. Attorney's Office for the Eastern District of Pennsylvania.

The company did not provide any further details about the subpoena.

Also on Tuesday, Johnson & Johnson cited the recalls in cutting its full-year profit outlook.

Johnson & Johnson (JNJ, Fortune 500) said it now expects to earn between $4.65 to $4.75 a share, excluding items, for the full year. The company had earlier issued full-year guidance of between $4.80 to $4.90 a share.

Analysts, on average, had expected the company to earn $4.80 a share for the year, according to Thomson Reuters.

The company's stock fell 2.5% in early trading.

The forecast reflects the impact of recalls announced earlier this year of Tylenol, Motrin, Benadryl and other medicines, as well as the suspension of a plant in Fort Washington, Pa.

In early May, McNeil recalled millions of children's Tylenol, Motrin and other over-the-counter medicines over quality concerns. Those products were made by McNeil, Johnson & Johnson's manufacturing division. The Fort Washington facility made all of the company's liquid pediatric drugs. (Read 'Tylenol plant: From bad to worse')

McNeil subsequently shut the plant for production after the Food and Drug Administration issued a scathing inspection report.

Last week, McNeil announced it was laying off 300 of more than 400 Fort Washington workers.

The company said it is taking steps to use other plants to make many of the products that it had manufactured in Fort Washington. But McNeil has also said that most of the products made in Fort Washington will not be available in stores before the end of the year.

Johnson & Johnson said the successive recalls, as well as the shutdown of the Fort Washington plant, resulted in a 27.5% sales drop of the company's over-the-counter drugs in the United States.

During a conference call with analysts Tuesday, Johnson & Johnson executives said the recalls and the shutdown of the Fort Washington plant will reduce annual sales of its over-the-counter products by about $600 million.

Meanwhile, another drugmaking facility operated by Johnson & Johnson -- this one in Lancaster, Pa., -- was flagged by the FDA last week over quality concerns. To top of page

Search for Jobs

Index Last Change % Change
Dow 20,975.09 -21.03 -0.10%
Nasdaq 6,025.23 -0.27 -0.00%
S&P 500 2,387.45 -1.16 -0.05%
Treasuries 2.31 -0.02 -0.69%
Data as of 5:39am ET
Company Price Change % Change
Bank of America Corp... 23.89 -0.09 -0.38%
Ford Motor Co 11.60 0.12 1.05%
Chesapeake Energy Co... 5.47 -0.04 -0.73%
General Electric Co 29.26 -0.19 -0.65%
Advanced Micro Devic... 13.41 -0.08 -0.59%
Data as of Apr 26
Sponsors

Sections

U.S. economy started the year with sluggish growth under the new administration. But overall the U.S. economy is in solid shape. More

Chris Sacca, an investor known for his early bets on Uber and Twitter announced Wednesday that he will stop investing in startups. More

Homeowners who sold their home in the first three months of this year saw an average price gain of $44,000 from purchase, according to a new report. More